β-Amyloid exacerbates inflammation in astrocytes lacking fatty acid amide hydrolase through a mechanism involving PPAR-α, PPAR-γ and TRPV1, but not CB1 or CB2 receptors

British Journal of Pharmacology

Volumn 166, Issue 4, 2012, Pages 1474-1489

  Benito, Cristina ^a   Tolõn, Rosa María ^a   Castillo, Ana Isabel ^a   Ruiz Valdepeñas, Lourdes ^a   Martínez Orgado, José Antonio ^b   Fernández Sánchez, Francisco Javier ^a   Vázquez, Carmen ^a   Cravatt, Benjamin F ^c   Romero, Julián ^a  

^a HOSPITAL UNIVERSITARIO FUNDACIÓN ALCORCÓN   (Spain)

^b HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^c SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

astrocytes; beta amyloid; Endocannabinoids; Neuroinflammation; PPAR; TRPV1

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; ANANDAMIDE; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CYCLOOXYGENASE 2; FATTY ACID AMIDASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE P38; N OLEOYLETHANOLAMINE; PALMIDROL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TUMOR NECROSIS FACTOR ALPHA; VANILLOID RECEPTOR 1;

ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASTROCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE EXACERBATION; ENCEPHALITIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FAAH GENE; GENE; GENE DELETION; GENE FUNCTION; GENE INACTIVATION; INTRACELLULAR SIGNALING; MOUSE; NEUROTOXICITY; NEWBORN; NONHUMAN; PATHOPHYSIOLOGY; PHARMACOLOGICAL BLOCKING; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING; WILD TYPE;

AMIDOHYDROLASES; AMYLOID BETA-PEPTIDES; ANIMALS; ANIMALS, NEWBORN; ASTROCYTES; CELLS, CULTURED; CYCLOOXYGENASE 2; CYTOKINES; ENZYME INHIBITORS; GENE EXPRESSION REGULATION; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NERVE TISSUE PROTEINS; NEURONS; NITRIC OXIDE SYNTHASE TYPE II; PEPTIDE FRAGMENTS; PPAR ALPHA; PPAR GAMMA; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; RNA, MESSENGER; TRPV CATION CHANNELS;

EID: 84861302815     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2012.01889.x     Document Type: Article

References (69)

1. th Edition. Br J Pharmacol 164 (Suppl. 1): S1-S324.
2. Allan SM, Rothwell NJ, (2003). Inflammation in central nervous system injury. Philos Trans R Soc London B Biol Sci 358: 1669-1677.
3. Amantini C, Mosca M, Nabissi M, Lucciarini R, Caprodossi S, Arcella A, et al,. (2007). Capsaicin-induced apoptosis of glioma cells is mediated by TRPV1 vanilloid receptor and requires p38 MAPK activation. J Neurochem 102: 977-990.
4. Bamberger ME, Harris ME, McDonald DR, Husemann J, Landreth GE, (2003). A cell surface receptor complex for fibrillar β-amyloid mediates microglial activation. J Neurosci 23: 2665-2674.
5. Benito C, Nunez E, Tolon RM, Carrier EJ, Rabano A, Hillard CJ, et al,. (2003). Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer's disease brains. J Neurosci 23: 11136-11141.
6. Benito C, Tolõn RM, Núñez E, Pazos MR, Romero J, (2007). Neuroinflammation and the glial endocannabinoid system. In:, Koffalvi A, (ed.). Cannabinoids and the Brain. Springer Verlag: Berlin, pp. 314-334.
7. Bouaboula M, Hilairet S, Marchand J, Fajas L, Le Fur G, Casellas P, (2005). Anandamide induced PPARgamma transcriptional activation and 3T3-L1 preadipocyte differentiation. Eur J Pharmacol 517: 174-181.
8. Burdick D, Soreghan B, Kwon M, Kosmoski J, Knauer M, Henschen A, et al,. (1992). Assembly and aggregation properties of synthetic Alzheimer's A4/beta amyloid peptide analogs. J Biol Chem 267: 546-554.
9. Combs CK, Bates P, Karlo C, Landreth GE, (2001). Regulation of beta-amyloid stimulated proinflammatory responses by peroxisome proliferator-activated receptor alpha. Neurochem Int 39: 449-457.
10. Coraci IS, Husemann J, Berman JW, Hulette C, Dufour JH, Campanella GK, et al,. (2002). CD36, a class B scavenger receptor, is expressed on microglia in Alzheimer's disease brains and can mediate production of reactive oxygen species in response to β-amyloid fibrils. Am J Pathol 160: 101-112.
11. Correa F, Mestre L, Docagne F, Borrell J, Guaza C, (2009). The endocannabinoid anandamide from immunomodulation to neuroprotection. Implications for multiple sclerosis. Vitam Horm 81: 207-230.
12. Correa F, Hernangõmez M, Mestre L, Loría F, Spagnolo A, Docagne F, et al,. (2010). Anandamide enhance IL-10 production in activated microglia by targeting CB(2) receptors: roles of ERK1/2, JNK, and NF-kappaB. Glia 58: 135-147.
13. Cravatt BF, Demarest K, Patricelli MP, Bracey MH, Giang DK, Martin BR, et al,. (2001). Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc Natl Acad U S A 98: 9371-9376.
14. De Lago E, Gustafsson SB, Fernández-Ruiz J, Nilsson J, Jacobsson SOP, Fowler CJ, (2006). Acyl-based anandamide uptake inhibitors cause rapid toxicity to C6 glioma cells at pharmacologically relevant concentrations. J Neurochem 99: 677-688.
15. De Petrocellis L, Davis JB, Di Marzo V, (2001). Palmitoylethanolamide enhances anandamide stimulation of human vanilloid VR1 receptors. FEBS Lett 506: 253-256.
16. Doly S, Fischer J, Salio C, Conrath M, (2004). The vanilloid receptor-1 is expressed in rat spinal dorsal horn astrocytes. Neurosci Lett 357: 123-126.
17. Drew PD, Xu J, Storer PD, Chavis JA, Racke MK, (2006). Peroxisome proliferator-activated receptor agonist regulation of glial activation: relevance to CNS inflammatory disorders. Neurochem Int 49: 183-189.
18. Esposito G, Iuvone T, Savani C, Scuderi C, De Filippis D, Papa M, et al,. (2007). Opposing control of cannabinoid receptor stimulation on amyloid-beta-induced reactive gliosis: in vitro and in vivo evidence. J Pharmacol Exp Ther 322: 1144-1152.
19. Fernandez-Ruiz JJ, Gonzalez S, Romero J, Ramos JA, (2005). Cannabinoids in neurodegeneration and neuroprotection. In:, Mechoulam R, (ed.). Cannabinoids as Therapeutics. Birkhäuser Verlag: Basel, Switzerland, pp. 79-109.
20. Fowler CJ, Rojo ML, Rodríguez-Gaztelumendi A, (2010). Modulation of the endocannabinoid system: neuroprotection or neurotoxicity? Exp Neurol 224: 37-47.
21. Heneka MT, Klockgether T, Feinstein DL, (2000). Peroxisome proliferator-activated receptor-gamma ligands reduce neuronal inducible nitric oxide synthase expression and cell death in vivo. J Neurosci 20: 6862-6867.
22. Hu SSJ, Bradshaw HB, Benton VM, Chen JSC, Huang SM, Minassi A, et al,. (2009). The biosynthesis of N-arachidonoyl dopamine (NADA), a putative endocannabinoid and endovanilloid, via conjugation of arachidonic acid with dopamine. Prostaglandins Leukot Essent Fatty Acids 81: 291-301.
23. Hwang J, Adamson C, Butler D, Janero DR, Makryiannis A, Bahr BA, (2010). Enhancement of endocannabinoid signalling by fatty acid amide hydrolase inhibition: a neuroprotective therapeutic modality. Life Sci 86: 615-623.
24. Jiang Q, Heneka M, Landreth GE, (2008). The role of peroxisome proliferator-activated receptor-gamma (PPARgamma) in Alzheimer's disease: therapeutic implications. CNS Drugs 22: 1-14.
25. Jung KM, Astarita G, Yasar S, Vasilevko V, Cribbs DH, Head E, et al,. (2011). An amyloid b(42)-dependent deficit in anandamide mobilization is associated with cognitive dysfunction in Alzheimer's disease. Neurobiol Aging. doi: 10.1016/j.neurobiolaging.2011.03.012.
26. Karaliota S, Siafaka-Kapadai A, Gontinou C, Psarra K, Mavri-Vavayanni M, (2009). Anandamide increases the differentiation of rat adipocytes and causes PPARgamma and CB1 receptor upregulation. Obesity 17: 1830-1838.
27. Karanian DA, Brown QB, Makryiannis A, Kosten TA, Bahr BA, (2005). Dual modulation of endocannabinoid transport and fatty acid amide hydrolase protects against excitotoxicity. J Neurosci 25: 7813-7820.
28. Koenigsknecht-Talboo J, Landreth G, (2005). Microglial phagocytosis induced by fibrillar β-amyloid and IgGs are differentially regulated by proinflammatory cytokines. J Neurosci 25: 8240-8249.
29. Kozak KR, Crews BC, Morrow JD, Wang LH, Ma YH, Weinander R, et al,. (2002). Metabolism of the endocannabinoids, 2-arachidonylglycerol and anandamide, into prostaglandin, thromboxane, and prostacyclin glycerol esters and ethanolamides. J Biol Chem 277: 44877-44885.
30. Lim JH, Gibbons HM, O'Carroll SJ, Narayan PJ, Faull RLM, Dragunow M, (2007). Extracellular signal-regulated kinase involvement in human astrocyte migration. Brain Res 1164: 1-13.
31. Liu Y, Walter S, Stagi M, Cherny D, Letiembre M, Schulz-Schaeffer H, et al,. (2005). LPS receptor (CD14): a receptor for phagocytosis of Alzheimer's amyloid peptide. Brain 128: 1778-1789.
32. Long JZ, LaCava M, Jin X, Cravatt BF, (2011). An anatomical and temporal portrait of physiological substrates for fatty acid amide hydrolase. J Lipid Res 52: 337-344.
33. Lorenzo A, Yankner BA, (1994). Beta-amyloid neurotoxicity requires fibril formation and is inhibited by Congo red. Proc Natl Acad Sci U S A 91: 12243-12247.
34. Luna-Medina R, Cortes-Canteli M, Alonso M, Santos A, Martinez A, Perez-Castillo A, (2005). Regulation of inflammatory response in neural cells in vitro by thiadiazolidinones derivatives through peroxisome proliferator- activated receptor gamma activation. J Biol Chem 280: 21453-21462.
35. Maccarrone M, Finazzi-Agrõ A, (2003). The endocannabinoid system, anandamide and the regulation of mammalian cell apoptosis. Cell Death Differ 10: 946-955.
36. Maccarrone M, Dainese E, Oddi S, (2010). Intracellular trafficking of anandamide: new concepts for signalling. Trends Biochem Sci 35: 601-608.
37. McCarthy KD, de Vellis J, (1980). Preparation of separate astroglial and oligodendroglial cell cultures from rat cerebral tissue. J Cell Biol 85: 890-902.
38. Molina-Holgado F, Lledõ A, Guaza C, (1997). Anandamide suppresses nitric oxide and TNF-alpha responses to Theiler's virus or endotoxin in astrocytes. Neuroreport 8: 1929-1933.
39. Molina-Holgado F, Molina-Holgado E, Guaza C, (1998). The endogenous cannabinoid anandamide potentites interleukin-6 production by astrocytes infected with Theiler's murine encephalomyelitis virus by a receptor-mediated pathway. FEBS Lett 433: 139-142.
40. Molina-Holgado F, Molina-Holgado E, Guaza C, Rothwell NJ, (2002). Role of CB1 and CB2 receptors in the inhibitory effects of cannabinoids on lipopolysaccharide-induced nitric oxide release in astrocyte cultures. J Neurosci Res 67: 829-836.
41. Mukhopadhyay P, Horváth B, Rajesh M, Matsumoto S, Saito K, Bátkai S, et al,. (2011). Fatty acid amide hydrolase is a key regulator of endocannabinoid-induced myocardial tissue injury. Free Radic Biol Med 50: 179-195.
42. Naslund J, Haroutunian V, Mosh R, Davis KL, Davies P, Greengard P, et al,. (2000). Correlation between elevated levels of amyloid-beta peptide in the brain and cognitive decline. JAMA 283: 1571-1577.
43. Noonan J, Tanveer R, Klompas A, Gowran A, McKiernan J, Campbell VA, (2010). Endocannabinoids prevent beta-amyloid-mediated lysosomal destabilization in cultured neurons. J Biol Chem 285: 38543-38554.
44. Nuñez E, Benito C, Tolõn RM, Hillard CJ, Griffin WS, Romero J, (2008). Glial expression of cannabinoid CB(2) receptors and fatty acid amido hydrolase are beta amyloid-linked events in Down's syndrome. Neuroscience 151: 104-110.
45. O'Sullivan SE, (2007). Cannabinoids go nuclear: evidence for activation of peroxisome proliferator-activated receptors. Br J Pharmacol 152: 576-582.
46. Ortega-Gutiérrez S, Molina-Holgado E, Guaza C, (2005). Effect of anandamide uptake inhibition in the production of nitric oxide and in the release of cytokines in astrocyte cultures. Glia 52: 163-168.
47. Patel S, Carrier EJ, Ho WS, Rademacher DJ, Cunningham S, Reddy DS, et al,. (2005). The postmortal accumulation of brain N-arachidoylethanolamine (anandamide) is dependent upon fatty acid amide hydrolase activity. J Lipid Res 46: 342-349.
48. Pertwee R, (2008). Ligands that target cannabinoid receptors in the brain: from THC to anandamide and beyond. Addict Biol 13: 147-159.
49. Pertwee R, Howlett AC, Abood ME, Alexander SPH, Di Marzo V, Elphick MR, et al,. (2010). International Union of basic and clinical pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB1 and CB2. Pharmacol Rev 62: 588-631.
50. Ramírez BG, Blazquez C, Gomez del Pulgar T, Guzman M, De Ceballos ML, (2005). Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. J Neurosci 25: 1904-1913.
51. Romero J, Hillard CJ, Calero M, Rabano A, (2002). Fatty acid amide hydrolase localization in the human central nervous system: an immunohistochemical study. Mol Brain Res 100: 85-93.
52. Scuderi C, Esposito G, Blasio A, Valenza M, Arietti P, Steardo L, et al,. (2011). Palmitoylethanolamide counteracts reactive astrogliosis induced by beta-amyloid peptide. J Cell Mol Med 15: 2664-2674.
53. Semple BD, Frugier T, Morganti-Kossmann MC, (2011). CCL2 modulates cytokine production in cultured mouse astrocytes. J Neuroinflammation 7: 67.
54. Shivachar AC, (2007). Cannabinoids inhibit sodium-dependent, high affinity excitatory amino acid transport in cultured rat cortical astrocytes. Biochem Pharmacol 73: 2004-2011.
55. Siegmund SV, Seki E, Osawa Y, Uchinami H, Cravatt BF, Schwabe RF, (2006). Fatty acid amide hydrolase determines anandamide-induced cell death in the liver. J Biol Chem 281: 10431-10438.
56. Starowicz K, Nigam S, Di Marzo V, (2007). Biochemistry and pharmacology of endovanilloids. Pharmacol Ther 114: 13-33.
57. Stella N, (2004). Cannabinoid signalling in glial cells. Glia 48: 267-277.
58. Strohmeyer R, Rogers J, (2001). Molecular and cellular mediators of Alzheimer's disease inflammation. J Alzheimers Dis 3: 131-157.
59. Tõth A, Boczán J, Kedei N, Lizanecz E, Bagi Z, Papp Z, et al,. (2005). Expression and distribution of vanilloid receptor 1 (TRPV1) in the adult rat brain. Brain Res Mol Brain Res 135: 162-168.
60. Tsou K, Nogueron MI, Muthian S, Sañudo-Peña MC, Hillard CJ, Deutsch DG, et al,. (1998). Fatty acid amide hydrolase is located preferentially in large neurons in the rat central nervous system as revealed by immunohsitochemistry. Neurosci Lett 254: 137-140.
61. Tuppo EE, Arias HR, (2005). The role of inflammation in Alzheimer's disease. Int J Biochem Cell Biol 37: 289-305.
62. Van der Stelt M, Mazzola C, Esposito G, Matias I, Petrosino S, De Filippis D, et al,. (2006). Endocannabinoids and beta-amyloid-induced neurotoxicity in vivo: effect of pharmacological elevation of endocannabinoid levels. Cell Mol Life Sci 63: 1410-1424.
63. Vignali M, Benfenati V, Caprini M, Anderova M, Nobile M, Ferroni S, (2009). The endocannabinoid anandamide inhibits potassium conductance in rat cortical astrocytes. Glia 57: 791-806.
64. Walter L, Franklin A, Witting A, Möller T, Stella N, (2002). Astrocytes in culture produce anandamide and other acylethanolamides. J Biol Chem 277: 20869-20876.
65. Wang HM, Zhao YX, Zhang S, Liu GD, Kang WY, Tang HD, et al,. (2010). PPARgamma agonist curcumin reduces the amyloid-beta-stimulated inflammatory responses in primary astrocytes. J Alzheimers Dis 20: 1189-1199.
66. Wyss-Coray T, (2006). Inflammation in Alzheimer's disease: driving force, bystander or beneficial response? Nat Med 12: 1005-1015.
67. Wyss-Coray T, McConlogue L, Kindy M, Schmidt AM, Du Yan S, Stern DM, (2001). Key signalling pathways regulate the biological activities and accumulation of amyloid-beta. Neurobiol Aging 22: 967-973.
68. Xu J, Drew PD, (2007). Peroxisome proliferator-activated receptor-gamma agonists suppress the production of IL-12 family cytokines by activated glia. J Immunol 178: 1904-1913.
69. Xu J, Chavis JA, Racke MK, Drew PD, (2006). Peroxisome proliferator-activated receptor-alpha and retinoid X receptor agonists inhibit inflammatory responses of astrocytes. J Neuroimmunol 176: 95-105.